Literature DB >> 26795398

Synthetic cannabinoid drug use as a cause or contributory cause of death.

Laura M Labay1, James L Caruso2, Thomas P Gilson3, Rebecca Jufer Phipps4, Laura D Knight5, Nikolas P Lemos6, Iain M McIntyre7, Robert Stoppacher8, Lee Marie Tormos9, Andrea L Wiens10, Erica Williams11, Barry K Logan12.   

Abstract

Adverse effects associated with synthetic cannabinoid use include agitation, psychosis, seizures and cardiovascular effects, all which may result in a lethal outcome. We report the collection of data from 25 medical examiner and coroner cases where the presence of synthetic cannabinoids was analytically determined. Participating offices provided case history, investigative and relevant autopsy findings and toxicology results along with the cause and manner of death determination. This information, with the agency and cause and manner of death determinations blinded, was sent to participants. Participants offered their opinions regarding the likely contribution of the toxicology findings to cause and manner of death. The results show that some deaths are being attributed to synthetic cannabinoids, with the highest risk areas being behavioral toxicity resulting in excited delirium, trauma or accidents and as contributing factors in subjects with pre-existing cardiopulmonary disease. While insufficient information exists to correlate blood synthetic cannabinoid concentrations to effect, in the absence of other reasonable causes, the drugs should be considered as a cause or contributory cause of death based on history and circumstances with supporting toxicological data.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cause and manner of death; Postmortem; Synthetic cannabinoids; Toxicology

Mesh:

Substances:

Year:  2016        PMID: 26795398     DOI: 10.1016/j.forsciint.2015.12.046

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  16 in total

1.  Increases in synthetic cannabinoids-related harms: Results from a longitudinal web-based content analysis.

Authors:  Francois R Lamy; Raminta Daniulaityte; Ramzi W Nahhas; Monica J Barratt; Alan G Smith; Amit Sheth; Silvia S Martins; Edward W Boyer; Robert G Carlson
Journal:  Int J Drug Policy       Date:  2017-06-01

2.  Pharmacokinetics and pharmacodynamics of the synthetic cannabinoid, 5F-MDMB-PICA, in male rats.

Authors:  Alex J Krotulski; Nancy Garibay; Donna Walther; Sara E Walton; Amanda L A Mohr; Barry K Logan; Michael H Baumann
Journal:  Neuropharmacology       Date:  2021-09-20       Impact factor: 5.250

3.  Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.

Authors:  Thomas F Gamage; Charlotte E Farquhar; Timothy W Lefever; Julie A Marusich; Richard C Kevin; Iain S McGregor; Jenny L Wiley; Brian F Thomas
Journal:  J Pharmacol Exp Ther       Date:  2018-03-16       Impact factor: 4.030

Review 4.  Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.

Authors:  Pal Pacher; Sabine Steffens; György Haskó; Thomas H Schindler; George Kunos
Journal:  Nat Rev Cardiol       Date:  2017-09-14       Impact factor: 32.419

5.  Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor.

Authors:  Ayat Zagzoog; Asher L Brandt; Tallan Black; Eunhyun D Kim; Riley Burkart; Mikin Patel; Zhiyun Jin; Maria Nikolaeva; Robert B Laprairie
Journal:  Sci Rep       Date:  2021-05-19       Impact factor: 4.379

6.  Synthetic Cannabinoid-Related Deaths in England, 2012-2019.

Authors:  Pruntha Yoganathan; Hugh Claridge; Lucy Chester; Amir Englund; Nicola J Kalk; Caroline S Copeland
Journal:  Cannabis Cannabinoid Res       Date:  2021-02-24

7.  Distribution of Synthetic Cannabinoids JWH-210, RCS-4 and Δ 9-Tetrahydrocannabinol After Intravenous Administration to Pigs.

Authors:  Nadine Schaefer; Mattias Kettner; Matthias W Laschke; Julia Schlote; Andreas H Ewald; Michael D Menger; Hans H Maurer; Peter H Schmidt
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 8.  Endo-cannabinoids system and the toxicity of cannabinoids with a biotechnological approach.

Authors:  Kamal Niaz; Fazlullah Khan; Faheem Maqbool; Saeideh Momtaz; Fatima Ismail Hassan; Navid Nobakht-Haghighi; Mahban Rahimifard; Mohammad Abdollahi
Journal:  EXCLI J       Date:  2017-05-15       Impact factor: 4.068

Review 9.  Cannabis, cannabinoids, and health.

Authors:  Genevieve Lafaye; Laurent Karila; Lisa Blecha; Amine Benyamina
Journal:  Dialogues Clin Neurosci       Date:  2017-09       Impact factor: 5.986

10.  The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities.

Authors:  Mitchell Longworth; Samuel D Banister; James B C Mack; Michelle Glass; Mark Connor; Michael Kassiou
Journal:  Forensic Toxicol       Date:  2016-04-27       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.